<DOC>
	<DOCNO>NCT00821093</DOCNO>
	<brief_summary>This study compare safety efficacy indacaterol 150 µg take daily ( o.d . ) versus salmeterol 50 µg take twice daily ( b.i.d ) patient 40 year old old chronic obstructive pulmonary disease .</brief_summary>
	<brief_title>Safety Efficacy Indacaterol Once Daily Versus Salmeterol Twice Daily Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Adults age ≥ 40 year Diagnosis chronic obstructive pulmonary disease ( COPD ) ( moderate severe classify GOLD Guidelines , 2007 ) : Smoking history least 10 pack year Postbronchodilator force expiratory volume 1 second ( FEV1 ) &lt; 80 % ≥ 30 % predict normal value screen Postbronchodilator FEV1/FVC ( force vital capacity ) &lt; 70 % screening Patients receive systemic corticosteroid COPD exacerbation 6 week prior screen runin period Patients require longterm oxygen therapy ( &gt; 15 h day ) chronic hypoxemia Patients respiratory tract infection within 6 week prior screen Patients concomitant pulmonary disease Patients history asthma Patients diabetes Type I uncontrolled diabetes Type II Any patient lung cancer history lung cancer Any patient active cancer history cancer le 5 year diseasefree survival time Patients history long QT syndrome whose QTc interval ( Fridericia 's ) measure screen prolonged Patients vaccinate live attenuate vaccine within 30 day prior screen runin period Patients unable successfully use dry powder inhaler device perform spirometry measurements Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>respiratory</keyword>
	<keyword>dyspnea</keyword>
	<keyword>breathlessness</keyword>
	<keyword>COPD</keyword>
	<keyword>indacaterol</keyword>
	<keyword>long-acting β2-agonist</keyword>
</DOC>